China Resources Double-Crane PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 5/6
China Resources Double-Crane PharmaceuticalLtd has a total shareholder equity of CN¥10.9B and total debt of CN¥686.4M, which brings its debt-to-equity ratio to 6.3%. Its total assets and total liabilities are CN¥16.5B and CN¥5.7B respectively. China Resources Double-Crane PharmaceuticalLtd's EBIT is CN¥1.4B making its interest coverage ratio -47.9. It has cash and short-term investments of CN¥2.7B.
Key information
6.3%
Debt to equity ratio
CN¥686.44m
Debt
| Interest coverage ratio | -47.9x |
| Cash | CN¥2.71b |
| Equity | CN¥10.89b |
| Total liabilities | CN¥5.66b |
| Total assets | CN¥16.55b |
Recent financial health updates
Recent updates
The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 29
China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement
Oct 21An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued
Sep 30We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease
Jul 16China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 24Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel
Mar 02Financial Position Analysis
Short Term Liabilities: 600062's short term assets (CN¥7.3B) exceed its short term liabilities (CN¥4.6B).
Long Term Liabilities: 600062's short term assets (CN¥7.3B) exceed its long term liabilities (CN¥1.1B).
Debt to Equity History and Analysis
Debt Level: 600062 has more cash than its total debt.
Reducing Debt: 600062's debt to equity ratio has increased from 0.8% to 6.3% over the past 5 years.
Debt Coverage: 600062's debt is well covered by operating cash flow (268%).
Interest Coverage: 600062 earns more interest than it pays, so coverage of interest payments is not a concern.